S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
Log in
NASDAQ:QURE

uniQure Stock Forecast, Price & News

$37.53
-0.55 (-1.44 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$36.91
Now: $37.53
$38.50
50-Day Range
$36.13
MA: $42.99
$50.67
52-Week Range
$34.38
Now: $37.53
$71.45
Volume367,958 shs
Average Volume412,254 shs
Market Capitalization$1.67 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.13
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure logo

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

112th out of 1,558 stocks

Pharmaceutical Preparations Industry

51st out of 638 stocks

Analyst Opinion: 4.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QURE
CUSIPN/A
Phone31-20-240-6000
Employees248

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.28 million
Book Value$7.41 per share

Profitability

Net Income$-124,200,000.00
Net Margins-2,553.30%

Miscellaneous

Market Cap$1.67 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$37.53
-0.55 (-1.44 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











uniQure (NASDAQ:QURE) Frequently Asked Questions

How has uniQure's stock been impacted by Coronavirus?

uniQure's stock was trading at $47.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, QURE shares have decreased by 21.1% and is now trading at $37.53.
View which stocks have been most impacted by COVID-19
.

Is uniQure a buy right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than uniQure?

Wall Street analysts have given uniQure a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but uniQure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is uniQure's next earnings date?

uniQure is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for uniQure
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) released its quarterly earnings results on Tuesday, October, 27th. The biotechnology company reported ($1.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.26 by $2.47. The biotechnology company earned $1.79 million during the quarter, compared to the consensus estimate of $96.58 million. uniQure had a negative return on equity of 43.95% and a negative net margin of 2,553.30%.
View uniQure's earnings history
.

What price target have analysts set for QURE?

13 equities research analysts have issued 1-year target prices for uniQure's shares. Their forecasts range from $52.00 to $85.00. On average, they expect uniQure's share price to reach $66.92 in the next year. This suggests a possible upside of 78.3% from the stock's current price.
View analysts' price targets for uniQure
or view Wall Street analyst' top-rated stocks.

Who are some of uniQure's key competitors?

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

Who are uniQure's key executives?

uniQure's management team includes the following people:
  • Mr. Matthew Craig Kapusta, CEO, CFO & Exec. Director (Age 49, Pay $908.63k)
  • Dr. Alexander E. Kuta Ph.D., Exec. VP of Operations (Age 61, Pay $610.61k)
  • Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Mr. Christian Klemt, Chief Accounting Officer (Age 48)
  • Mr. David Cerveny, Chief Legal Officer, Gen. Counsel & Sec. (Age 54)
  • Ms. Maria E. Cantor, Chief Communications Officer (Age 53)
  • Dr. Tamara Tugal Ph.D., MBA, Bus. Devel. Director
  • Mr. James Brady, Chief HR Officer
  • Mr. Jonathan Garen M.S., Chief Bus. Officer (Age 55)
  • Mr. Ricardo Dolmetsch Ph.D., Pres of R&D (Age 52)

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a number of institutional and retail investors. Top institutional investors include OneAscent Financial Services LLC (0.03%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Jack Kaye, Jeremy P Springhorn, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Robert Gut and Scott T Mcmillan.
View institutional ownership trends for uniQure
.

Which institutional investors are buying uniQure stock?

QURE stock was acquired by a variety of institutional investors in the last quarter, including OneAscent Financial Services LLC.
View insider buying and selling activity for uniQure
or or view top insider-buying stocks.

How do I buy shares of uniQure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $37.53.

How big of a company is uniQure?

uniQure has a market capitalization of $1.67 billion and generates $7.28 million in revenue each year. The biotechnology company earns $-124,200,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis. uniQure employs 248 workers across the globe.

What is uniQure's official website?

The official website for uniQure is www.uniqure.com.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.